The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
When a billionaire investor says eBay "needs to be on Ozempic," it signals how deeply semaglutide has entered the cultural conversation. But for real patients, the more important question is what this attention means for access, cost, and treatment options in 2025 and beyond.
Novo Nordisk is working to rebuild momentum around Wegovy with new clinical data and a growing drug pipeline. For patients considering semaglutide or comparing GLP-1 options, these developments have real implications for access, cost, and future treatment choices. Here's what you need to know.
Generic versions of semaglutide (the active ingredient in Ozempic) are becoming available in several countries, but U.S. patients face a longer wait due to patent protections. Here is what that means for your wallet, your treatment options, and what you can realistically do today.
FDA Commissioner Marty Makary is stepping down, with Kyle Diamantas stepping in as acting commissioner. For patients on GLP-1 medications like semaglutide or tirzepatide, this kind of transition raises real questions about drug approvals, compounding policy, and access. Here's what you actually need to know.
Novo Nordisk presented early data on an oral version of Wegovy at ECO2026, showing 21.6% weight loss in early responders and doubled improvements in mobility. Here's what the findings mean for patients weighing their GLP-1 options.
Dr. Reddy's is set to launch a generic version of semaglutide (the active ingredient in Ozempic) in Canada within days. This is a significant development for patients seeking more affordable GLP-1 access. Here's what it means for you, whether you're in Canada or watching for similar changes in the U.S.
The BALANCE Model is a federal initiative designed to expand GLP-1 medication access for Medicare and Medicaid patients with obesity. Paired with the Medicare GLP-1 Bridge program, it could significantly reduce out-of-pocket costs for millions of Americans. Here is what you need to know about eligibility, timing, and what to ask your doctor.
A major cost shift is coming for some Medicare enrollees this summer, with GLP-1 medications dropping to a $50 cap. This article breaks down who qualifies, which drugs are included, and what steps to take now to prepare.
